Ensure you understand any exclusions related to weight loss services, off-label use, or compounding
In the STEP-1 trial of 1,961 adults (Wilding and colleagues, Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 2021), participants on semaglutide 2.4 mg lost an average of 14.9 percent of their body weight at 68 weeks, compared to 2.4 percent on placebo
Complications of laparoscopic paraesophageal hernia repair
Third, media attention and influencer endorsements dramatically increased public awareness of GLP-1 effectiveness, creating patient demand that pressured healthcare systems to expand access
When paired with other fiber-rich ingredients, peanut butter significantly enhances the overall GLP-1 response of a snack